Latest Thesis
Pfizer: the post-COVID reset still has to prove durable earnings power
Pfizer reported FY2025 revenue of $62.6 billion and Q1 2026 revenue of $14.5 billion. The thesis depends on portfolio durability, oncology integration, patent cliffs, operating cash flow, debt capacity and pipeline execution.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
Recent Reports
Compact report index for this company.
ReportTypeUpdatedReadActions
Pfizer: the post-COVID reset still has to prove durable earnings powerPfizer reported FY2025 revenue of $62.6 billion and Q1 2026 revenue of $14.5 billion. The thesis depends on portfolio durability, oncology integration, patent cliffs, operating cash flow, debt capacity and pipeline execution.NYSEMay 20, 2026Research reportReadSlides